BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Global Biodefense - ECPv6.17.5.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Global Biodefense
X-ORIGINAL-URL:https://globalbiodefense.com
X-WR-CALDESC:Events for Global Biodefense
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20221030T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/Denver
BEGIN:DAYLIGHT
TZOFFSETFROM:-0700
TZOFFSETTO:-0600
TZNAME:MDT
DTSTART:20220313T090000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0600
TZOFFSETTO:-0700
TZNAME:MST
DTSTART:20221106T080000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0700
TZOFFSETTO:-0600
TZNAME:MDT
DTSTART:20230312T090000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0600
TZOFFSETTO:-0700
TZNAME:MST
DTSTART:20231105T080000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0700
TZOFFSETTO:-0600
TZNAME:MDT
DTSTART:20240310T090000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0600
TZOFFSETTO:-0700
TZNAME:MST
DTSTART:20241103T080000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0700
TZOFFSETTO:-0600
TZNAME:MDT
DTSTART:20250309T090000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0600
TZOFFSETTO:-0700
TZNAME:MST
DTSTART:20251102T080000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20220313T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20221106T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20230312T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20231105T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20240310T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20241103T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20250309T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20251102T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230920
DTEND;VALUE=DATE:20230921
DTSTAMP:20230918T174503Z
CREATED:20230718T173326Z
LAST-MODIFIED:20230918T174503Z
UID:59243-1695168000-1695254399@globalbiodefense.com
SUMMARY:First WHO/Europe Indoor Air​ Conference 2023
DESCRIPTION:The First WHO/Europe Indoor Air​ Conference will be held 20 September 2023 in Bern\, Switzerland and via virtual participation. \nThe COVID-19 pandemic demonstrated the importance of ventilation to mitigate the transmission of respiratory disease. \nBeyond COVID-19 there is growing awareness that exposure to pollutants in indoor environments has a substantial impact on health\, productivity and performance. Large numbers of buildings do not have good ventilation or good indoor air quality\, and there are multiple other considerations including climate change\, energy\, comfort\, noise and security. \nHighlighted presentations include: \n\nThe indoor environment as a determinant for health\nInfection risk and IAQ in Swiss schools\nWhat do we need to achieve in buildings? What is realistic vs what is ideal?\nWhat do we know about the current state of IAQ in buildings?\nPandemic management through indoor pathogen transmission suppression – EU innovation funding\nChallenge and opportunity for Indoor Air – Learning from the pandemic\nImproving ventilation in Swiss buildings – IAQ as part of sustainability\nCompliance through information sharing in Belgium\nPriorities for improving indoor air in Switzerland\n\nThe event will be held in English and simultaneously translated in French\, German and Russian. \nPlease visit the WHO and Geneva Health Forum’s First WHO/Europe Indoor Air Conference website to register.
URL:https://globalbiodefense.com/event/first-who-europe-indoor-air-conference-2023/
LOCATION:Hotel Schweizerhof Bern & Spa\, Bahnhofpl. 11\, Bern\, 3001\, Switzerland
CATEGORIES:Conference
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230927
DTEND;VALUE=DATE:20230929
DTSTAMP:20230816T010636Z
CREATED:20230815T173825Z
LAST-MODIFIED:20230816T010636Z
UID:57610-1695772800-1695945599@globalbiodefense.com
SUMMARY:Government Biotechnology Innovation Summit
DESCRIPTION:Join government leaders at the forefront on how biotechnology is transforming the economic\, agricultural\, healthcare and security landscape of the U.S. \nThe 2023 Government Biotechnology Innovation Summit will be held 27-28 September 2023 in the DC Capitol Region. \nBe part of the discussion of the advancement of innovative biotechnology and biomanufacturing solutions across agencies and sectors as a means of furthering and securing U.S. National Interests. \nIn September 2022\, the White House announced an Executive Order launching a National Biotechnology and Bio-manufacturing Initiative with a $2 billion funding plan to further drive a national strategy for expanding the domestic bioeconomy and biomanufacturing capacity. \nThe Government Biotechnology Innovation Summit will offer a forum for leaders to discuss how the government employs biotechnology for national security purposes\, including biodefense initiatives\, surveillance of infectious diseases\, and the prevention and response to biological threats. \nHighlighted speakers include: \n\nRenee Wegrzyn\, PhD – Director\, Advanced Research Projects Agency for Health (ARPA-H)\nKerri Dugan\, PhD – Director\, Biological Technologies Office\, Defense Advanced Research Projects Agency (DARPA)\nPeter Marks\, MD\, PhD – Director\, Center for Biologics Evaluation and Research\, Food and Drug Administration (FDA)\nDeirdra Chester\, PhD – Director\, Office of the Chief Scientist\, US Department of Agriculture (USDA)\nCari Young\, ScM – Acting Division Director\, Biosafety\, Biosecurity\, and Emerging Biotechnology\, National Institutes of Health (NIH)\nSimon Malcomber\, PhD – Deputy Assistant Director\, Directorate for Biological Sciences\, National Science Foundation (NSF)\n\nThe Summit will also explore investing in research and development\, establishing regulations and guidelines\, and collaborating with academia and industry to harness the potential of biotechnology for the benefit of society as a whole. By harnessing the power of biotechnology through cooperation\, the government can improve public health outcomes through advanced diagnostics\, therapies\, and personalized medicine. Biotech innovations can also revolutionize sustainable agriculture by increasing crop yields\, developing drought and pest-resistant varieties\, and reducing environmental impact. \nPlease visit DSI’s Government Biotechnology Innovation Summit to register to attend. \nDefense Strategies Institute is an official partner of Global Biodefense
URL:https://globalbiodefense.com/event/government-biotechnology-innovation-summit/
LOCATION:The Sunset Room\, 165 Waterfront Street\, National Harbor\, MD\, 20754\, United States
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://globalbiodefense.com/wp-content/uploads/2023/08/biotechnology-innovation-1200x630-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20230929T100000
DTEND;TZID=America/New_York:20230929T113000
DTSTAMP:20230920T192004Z
CREATED:20230820T191510Z
LAST-MODIFIED:20230920T192004Z
UID:59298-1695981600-1695987000@globalbiodefense.com
SUMMARY:The Long Journey to Eliminate the Deadly U.S. Chemical Weapons Stockpile
DESCRIPTION:The CWC Coalition will host a webinar entitled ‘The End of an Era: The Long Journey to Eliminate the Deadly U.S. Chemical Weapons Stockpile’ on 29 September 2023. \nWhen the United States ratified the Chemical Weapons Convention (CWC) in 1997\, it took on the legal obligation and the complex technical and engineering task of destroying its massive Cold War-era chemical weapons stockpile\, which consisted of some 31\,500 tons (63\,000\,000 pounds) of deadly chemical agents much of which were loaded in various forms of munitions. \nAfter years of delay\, all U.S. declared chemical weapons stockpiles were irreversibly and verifiably destroyed in July 2023\, two months ahead of the Sept. 2023 deadline set by the Organization for the Prohibition of Chemical Weapons (OPCW). \nThe event is a major milestone in disarmament: the United States was the last declared stockpile possessor state to complete its safe and permanent demilitarization of chemical weapons. \nOn Sept. 29\, this webinar will feature perspectives from a senior Defense Department official on the long path to successfully eliminate the U.S. chemical arsenal\, and the experiences of two local leaders who worked to reshape the government’s original plans for chemical weapons destruction to reduce the risks to local communities where the U.S. stockpiles were once stored. \nSpeakers: \n\nKingston Reif\, deputy assistant secretary of defense for threat reduction and arms control\nIrene Kornelly\, chair of the Colorado Citizens’ Advisory Commission\nCraig Williams\, co-chair of the Kentucky Citizens’ Advisory Commission\nDaryl Kimball\, executive director\, Arms Control Association\, moderating\n\nThis discussion will be on the record. The webinar is organized by the Arms Control Association and the Chemical Weapons Convention Coalition. \nRSVP via Zoom
URL:https://globalbiodefense.com/event/the-long-journey-to-eliminate-the-deadly-u-s-chemical-weapons-stockpile/
CATEGORIES:Webinar-Webcast
LOCATION:https://us02web.zoom.us/webinar/register/7416946160158/WN_N3yOaJhBTaOPVD9IB80z-g#/registration
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231003
DTEND;VALUE=DATE:20231006
DTSTAMP:20230916T150439Z
CREATED:20230916T150439Z
LAST-MODIFIED:20230916T150439Z
UID:59214-1696291200-1696550399@globalbiodefense.com
SUMMARY:OneLab Summit 2023
DESCRIPTION:The CDC will host the OneLab Summit 2023 from 3-5 October 2023 online. This free\, three-day virtual summit connects laboratory professionals in real time to support a unified response to laboratory training needs. \nAttendance is open to anyone interested or involved in the laboratory profession. OneLab Summit programming is most relevant to people who provide education or training to clinical and public laboratory professionals. \nHighlighted topics include: \n\nMaximizing Lessons Learned from Past Outbreaks to Develop a Sustainable Laboratory Cross-training Program\nBiosafety Plan: Preparing Your Laboratory to Handle Emerging and Re-Emerging Pathogens\nHow Laboratories Should Prepare for Future Responses\nEvaluating Your Laboratory’s Risk Management Process Or Quality Improvement Process\nThe Role and Importance of DEIAB in Public Health Workforce Development to Advance Health Equity\nInterconnecting People for Planning and Preparedness\nOneLab REACH – What’s New and What’s Ahead\nUnderstanding CLIA and CAP Regulations to Advance Your Laboratory Career\nCreating a Training Needs Assessment For Your Laboratory\nLaboratory Staffing and Retention\nInnovative Student Recruitment to MLS and MLT Programs\n\nThis year\, OneLab Summit will feature a Virtual Exhibit Hall. Attendees can use this online space to highlight their organization’s programs\, resources\, success stories\, and more. \nPlease visit CDC’s OneLab Summit 2023 website to register.
URL:https://globalbiodefense.com/event/onelab-summit-2023/
CATEGORIES:Government Hosted,Webinar-Webcast
LOCATION:https://cdc.zoomgov.com/webinar/register/WN_tANOotpLSduPLwmczNXDVA#/registration
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231003T120000
DTEND;TZID=America/New_York:20231003T140000
DTSTAMP:20231008T183147Z
CREATED:20230922T155901Z
LAST-MODIFIED:20231008T183147Z
UID:59305-1696334400-1696341600@globalbiodefense.com
SUMMARY:Public-Private Partnerships to Distribute\, Dispense\, and Administer Medical Countermeasures
DESCRIPTION:The National Academies will host a workshop on “Public-Private Partnerships for Data-Informed Decision-Making to Distribute\, Dispense\, and Administer Medical Countermeasures” on October 3\, 2023.\n \nLessons learned from past health emergencies highlight the importance of public-private partnerships to facilitate and accelerate the research\, development\, and manufacturing of vaccines\, therapeutics\, and diagnostics (i.e.\, medical countermeasures). However\, less attention was given to public-private partnerships that enabled the successful implementation (distribution\, dispensing\, monitoring\, uptake\, and utilization) of medical countermeasures (MCMs)\, also known as the “last-mile.” \nThis is part of the Medical Countermeasures- Expanding Delivery and Increasing Uptake Through Public-Private Partnerships workshop series hosted by the National Academies Forum on Medical and Public Health Preparedness for Disasters and Emergencies. The series aims to examine lessons learned and future opportunities for public-private partnerships to facilitate the implementation of medical countermeasures to the public during a public health emergency. Speakers throughout the series will highlight various public-private partnership models deployed during recent health emergencies and discuss potential paths forward for public-private partnerships to facilitate successful implementation of medical countermeasures. \nVisit NASEM’s Medical Countermeasures- Expanding Delivery and Increasing Uptake Through Public-Private Partnerships workshop website to register.
URL:https://globalbiodefense.com/event/public-private-partnerships-to-distribute-dispense-and-administer-medical-countermeasures/
CATEGORIES:Webinar-Webcast
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231004T100000
DTEND;TZID=America/New_York:20231004T140000
DTSTAMP:20230421T224948Z
CREATED:20230421T224941Z
LAST-MODIFIED:20230421T224948Z
UID:57010-1696413600-1696428000@globalbiodefense.com
SUMMARY:Tunneling Nanotubes and Intracellular Protrusions Workshop
DESCRIPTION:The Tunneling Nanotubes and Intracellular Protrusions Workshop will be hosted 4 October 2023 by the Federation of American Societies for Experimental Biology (FASEB). \nThis FASEB Catalyst Conference will be an exciting forum for discussing new discoveries in the field of tunneling nanotubes and related cell protrusions\, and their potential implications for human disease. \nIn the past decade\, there has been an increased focus on novel cellular extensions and their potential roles in facilitating human diseases\, including neurologic diseases\, viral infectious diseases\, cancer\, and others. One of the exciting new aspects of this field is improved characterization and understanding of the functions and potential mechanisms of tunneling nanotubes (TNTs). TNTs are actin-based filamentous protrusions that are structurally distinct from filopodia. They form and connect cells at long distance and serve as direct conduits for intercellular communication in a wide range of cell types in vitro and in vivo. \nResearchers are increasingly entering this field and investigating the role of TNTs in mediating cancer cell invasion and drug resistance\, cellular transfer of proteins\, RNA or organelles\, and intercellular spread of infectious agents\, such as viruses\, bacteria and prions. \nPlease visit FASEB’s Tunneling Nanotubes and Intercellular Protrusions Workshop site to register.
URL:https://globalbiodefense.com/event/tunneling-nanotubes-and-intracellular-protrusions-workshop/
CATEGORIES:Workshop
LOCATION:https://us06web.zoom.us/webinar/register/WN_Lz8ZIPsdT6-vNzJ2xnwjFA#/registration
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231012T120000
DTEND;TZID=America/New_York:20231012T140000
DTSTAMP:20230922T160758Z
CREATED:20230922T160650Z
LAST-MODIFIED:20230922T160758Z
UID:59309-1697112000-1697119200@globalbiodefense.com
SUMMARY:Public-Private Partnerships for Acceptance and Uptake of Medical Countermeasures
DESCRIPTION:The National Academies will host a workshop on “Public-Private Partnerships for Acceptance and Uptake of Medical Countermeasures” on 12 October 2023.\n \nLessons learned from past health emergencies highlight the importance of public-private partnerships to facilitate and accelerate the research\, development\, and manufacturing of vaccines\, therapeutics\, and diagnostics (i.e.\, medical countermeasures). However\, less attention was given to public-private partnerships that enabled the successful implementation (distribution\, dispensing\, monitoring\, uptake\, and utilization) of medical countermeasures (MCMs)\, also known as the “last-mile.” \nThis is part of the Medical Countermeasures- Expanding Delivery and Increasing Uptake Through Public-Private Partnerships workshop series hosted by the National Academies Forum on Medical and Public Health Preparedness for Disasters and Emergencies. The series aims to examine lessons learned and future opportunities for public-private partnerships to facilitate the implementation of medical countermeasures to the public during a public health emergency. Speakers throughout the series will highlight various public-private partnership models deployed during recent health emergencies and discuss potential paths forward for public-private partnerships to facilitate successful implementation of medical countermeasures. \nVisit NASEM’s Medical Countermeasures- Expanding Delivery and Increasing Uptake Through Public-Private Partnerships workshop website to register.
URL:https://globalbiodefense.com/event/public-private-partnerships-for-acceptance-and-uptake-of-medical-countermeasures/
CATEGORIES:Webinar-Webcast
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231017T120000
DTEND;TZID=America/New_York:20231017T140000
DTSTAMP:20230922T161025Z
CREATED:20230922T161025Z
LAST-MODIFIED:20230922T161025Z
UID:59311-1697544000-1697551200@globalbiodefense.com
SUMMARY:Public-Private Partnerships for Dispensing and Administration of Medical Countermeasures
DESCRIPTION:The National Academies will host a workshop on “Public-Private Partnerships for Dispensing and Administration of Medical Countermeasures” on 17 October 2023.\n \nLessons learned from past health emergencies highlight the importance of public-private partnerships to facilitate and accelerate the research\, development\, and manufacturing of vaccines\, therapeutics\, and diagnostics (i.e.\, medical countermeasures). However\, less attention was given to public-private partnerships that enabled the successful implementation (distribution\, dispensing\, monitoring\, uptake\, and utilization) of medical countermeasures (MCMs)\, also known as the “last-mile.” \nThis is part of the Medical Countermeasures- Expanding Delivery and Increasing Uptake Through Public-Private Partnerships workshop series hosted by the National Academies Forum on Medical and Public Health Preparedness for Disasters and Emergencies. The series aims to examine lessons learned and future opportunities for public-private partnerships to facilitate the implementation of medical countermeasures to the public during a public health emergency. Speakers throughout the series will highlight various public-private partnership models deployed during recent health emergencies and discuss potential paths forward for public-private partnerships to facilitate successful implementation of medical countermeasures. \nVisit NASEM’s Medical Countermeasures- Expanding Delivery and Increasing Uptake Through Public-Private Partnerships workshop website to register.
URL:https://globalbiodefense.com/event/public-private-partnerships-for-dispensing-and-administration-of-medical-countermeasures/
CATEGORIES:Webinar-Webcast
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231022
DTEND;VALUE=DATE:20231026
DTSTAMP:20230421T235537Z
CREATED:20230421T235537Z
LAST-MODIFIED:20230421T235537Z
UID:57022-1697932800-1698278399@globalbiodefense.com
SUMMARY:Tissue\, Matrix\, and Pathobiology: Joint Meeting of ASMB\, HCS\, and ASIP
DESCRIPTION:Tissue\, Matrix\, and Pathobiology will be held 22-25 October 2023 in Salt Lake City\, Utah. \nThis event is an exciting new multidisciplinary and collaborative joint meeting of the American Society for Matrix Biology (ASMB)\, The Histochemical Society (HCS)\, and the American Society for Investigative Pathology (ASIP). \nWho Should Attend\nStudents\, trainees\, investigators\, and educators who are working on cutting-edge basic\, clinical\, and translational research related to biology of cells and tissues\, as well as molecular and cellular alterations that drive disease processes. \nScientific Programming\nThe scientific program includes award lectures\, plenary sessions\, symposia\, and workshops featuring speakers who are leaders in their respective fields of study. Thematic highlights include: \n\nExtracellular Matrix Biology\nLiver Pathobiology\nCardiovascular Diseases\nECM Receptors\nPathobiology of Fibrosis\nCancer Pathobiology\nMatrix Disorders\nNeuropathology\nOrganoid Models of Disease\nMechanobiology\nInflammatory and Infectious diseases\nCell-Matrix Interactions\n\nHighlighted presentations include: \n\nMucosal Pathobiology – Cellular and Microbial Cross-Talk on the Mucosal Interfaces\nLiver Pathobiology – Mechanisms of Hepatoxicity and Liver Injury\nThe Tissue Engineering and Regenerative Medicine International Society\, Inc. (TERMIS)\nHigher Order Multi-Analyte Interrogation of Tissue\nViral Persistence (What Did COVID Teach Us About Preparing for the Next Pandemic)\nCardiovascular Pathobiology – Ramifications of SARS-CoV-2 Infection on the Heart\nLiver Pathobiology – Liver Growth Control: From Maintenance and Regeneration to Disease\nMatrix Degradation: MMPs\, ADAMTS\, Proteases\nNeuropathology and Neuro-Inflammation\nOrganoids to Study ECM Signaling\nInfection and ECM\nMatricellular Proteins\nRespiratory Viral Pathogens\nInfectious Disease – Utilizing Alternative Model Systems to Study Infectious Diseases\nDigital Pathology and Artificial Intelligence Applications in the Biotech Industry\nOrganoids and 3-D Models\n\nThe meeting will also feature education and career development sessions that are focused on the needs of the current generation of trainees and young investigators. A generous scholar award program will provide travel grants for trainees and junior faculty who are members of the participating Societies. \nPlease visit ASIP’s Tissue\, Matrix\, and Pathobiology 2023 Joint Meeting website for more information and to register.
URL:https://globalbiodefense.com/event/tissue-matrix-and-pathobiology-joint-meeting-of-asmb-hcs-and-asip/
LOCATION:The Grand America Hotel\, 555 Main St\, Salt Lake City\, UT\, 84111\, United States
CATEGORIES:Conference
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231026T120000
DTEND;TZID=America/New_York:20231026T140000
DTSTAMP:20230922T161311Z
CREATED:20230922T161228Z
LAST-MODIFIED:20230922T161311Z
UID:59314-1698321600-1698328800@globalbiodefense.com
SUMMARY:Public-Private Partnerships for Distribution of Medical Countermeasures
DESCRIPTION:The National Academies will host a workshop on “Public-Private Partnerships for Distribution of Medical Countermeasuress” on 26 October 2023.\n \nLessons learned from past health emergencies highlight the importance of public-private partnerships to facilitate and accelerate the research\, development\, and manufacturing of vaccines\, therapeutics\, and diagnostics (i.e.\, medical countermeasures). However\, less attention was given to public-private partnerships that enabled the successful implementation (distribution\, dispensing\, monitoring\, uptake\, and utilization) of medical countermeasures (MCMs)\, also known as the “last-mile.” \nThis is part of the Medical Countermeasures- Expanding Delivery and Increasing Uptake Through Public-Private Partnerships workshop series hosted by the National Academies Forum on Medical and Public Health Preparedness for Disasters and Emergencies. The series aims to examine lessons learned and future opportunities for public-private partnerships to facilitate the implementation of medical countermeasures to the public during a public health emergency. Speakers throughout the series will highlight various public-private partnership models deployed during recent health emergencies and discuss potential paths forward for public-private partnerships to facilitate successful implementation of medical countermeasures. \nVisit NASEM’s Medical Countermeasures- Expanding Delivery and Increasing Uptake Through Public-Private Partnerships workshop website to register.
URL:https://globalbiodefense.com/event/public-private-partnerships-for-distribution-of-medical-countermeasures/
CATEGORIES:Webinar-Webcast
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231102T120000
DTEND;TZID=America/New_York:20231102T140000
DTSTAMP:20231030T160122Z
CREATED:20230922T161543Z
LAST-MODIFIED:20231030T160122Z
UID:59316-1698926400-1698933600@globalbiodefense.com
SUMMARY:Future Opportunities: Levers and Systems for Public-Private Partnerships to Distribute\, Dispense\, and Administer Medical Countermeasures
DESCRIPTION:The National Academies will host a workshop on “Future Opportunities: Levers and Systems for Public-Private Partnerships to Distribute\, Dispense\, and Administer Medical Countermeasures” on 2 November 2023.\n \nLessons learned from past health emergencies highlight the importance of public-private partnerships to facilitate and accelerate the research\, development\, and manufacturing of vaccines\, therapeutics\, and diagnostics (i.e.\, medical countermeasures). However\, less attention was given to public-private partnerships that enabled the successful implementation (distribution\, dispensing\, monitoring\, uptake\, and utilization) of medical countermeasures (MCMs)\, also known as the “last-mile.” \nThis is part of the Medical Countermeasures- Expanding Delivery and Increasing Uptake Through Public-Private Partnerships workshop series hosted by the National Academies Forum on Medical and Public Health Preparedness for Disasters and Emergencies. The series aims to examine lessons learned and future opportunities for public-private partnerships to facilitate the implementation of medical countermeasures to the public during a public health emergency. Speakers throughout the series will highlight various public-private partnership models deployed during recent health emergencies and discuss potential paths forward for public-private partnerships to facilitate successful implementation of medical countermeasures. \nVisit NASEM’s Medical Countermeasures- Expanding Delivery and Increasing Uptake Through Public-Private Partnerships workshop website to register.
URL:https://globalbiodefense.com/event/future-opportunities-levers-and-systems-for-public-private-partnerships-to-distribute-dispense-and-administer-medical-countermeasures/
CATEGORIES:Webinar-Webcast
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231103
DTEND;VALUE=DATE:20231104
DTSTAMP:20231101T174924Z
CREATED:20231101T174547Z
LAST-MODIFIED:20231101T174924Z
UID:59429-1698969600-1699055999@globalbiodefense.com
SUMMARY:One Health Day 2023
DESCRIPTION:One Health Day is observed annually on 3 November to raise global awareness about the importance of One Health collaborations. \nThis global awareness campaign brings attention to the need for a One Health approach to address shared health threats at the human-animal-environment interface and promote best practices across all sectors. \nThe theme for this year is Act Together for One Health. \nZoonotic diseases are becoming a growing health threat worldwide\, with increasing reports of outbreaks in diverse regions. The risk of emerging and reemerging disease spillover and burden has been augmented by considerable interactions among animals\, humans\, and ecosystems. The One Health approach is critical to addressing public health threats by integrating environmental issues. Emerging diseases such as Ebola\, MERS-CoV\, and COVID-19\, underline the need for concerted action across sectors. \nIn October 2022\, the Quadripartite\, consisting of the Food and Agriculture Organization of the United Nations (FAO)\, the United Nations Environment Programme (UNEP)\, the World Health Organization (WHO)\, and the World Organisation for Animal Health (WOAH\, formerly OIE)\, launched a new One Health Joint Plan of Action. This plan has the objective of establishing a comprehensive framework for enhancing our ability to collectively prevent\, predict\, detect\, and respond to health threats by integrating systems and building capacity. \nYou can celebrate One Health Day every day by committing to working with experts in other sectors to achieve better health outcomes for all. \n \nResources: \n\nOne Health – Basics\nOne Health Course Series\nOne Health High-Level Expert Panel (OHHLEP)\nTripartite Zoonosis Guide\nUnited Against Rabies\nStrengthening collaboration on One Health\nOne Health Initiative\nEnvironment\, Climate Change and Health\nHuman-Animal Interface Team\nInternational Health regulation\nNeglected Tropical Diseases\nNutrition and Food Safety\nSurveillance\, Prevention and Control of Antimicrobial Resistance\nA Compendium of Measures to Prevent Zoonotic Diseases Associated with Non-Traditional Pets\n\nSources: CDC\, UN Environment Programme\, ISID
URL:https://globalbiodefense.com/event/one-health-day-2023/
CATEGORIES:Awareness Event
ATTACH;FMTTYPE=image/jpeg:https://globalbiodefense.com/wp-content/uploads/2023/11/one-health-day-2023.jpg
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231106T120000
DTEND;TZID=America/New_York:20231106T133000
DTSTAMP:20231102T172033Z
CREATED:20231102T171412Z
LAST-MODIFIED:20231102T172033Z
UID:59435-1699272000-1699277400@globalbiodefense.com
SUMMARY:Charting a Responsible Future in AI & Biosecurity: Understanding Technology Capabilities
DESCRIPTION:The National Academies will host a webinar on November 6 on Charting a Responsible Future in AI & Biosecurity. \nOrganized by the Health and Medicine Division’s Forum on Microbial Threats and the Division of Earth and Life Studies’ Board on Life Sciences\, this is the first of two sessions bringing together technology developers\, researchers\, and policymakers working at the intersection of foundation model-based artificial intelligence (AI) and biological research to explore the impact of these technologies on innovation\, potential biosecurity risks\, and promising solutions. \nThe first session on November 6 will examine the technological capabilities and bridge the needs for risk management between developers and policymakers. \nHighlighted agenda items and strategic questions include: \n\nOverall framing: how close are we to achieving a full understanding of the genotype-to-phenotype relationship?\nBeneficial application of machine learning to develop tools that mitigate biosecurity risks\nand potential dual-use applications\nApplication of foundation models to protein design and implications for biosecurity\nDraft framework on control points and addressing risks through each mechanism\nConsidering the real vs projected risks landscape in life sciences research\, and practical approaches to address each\nThe true risks for misuse present day and in the future: What are the risks for intentional misuse? For accidental misuse?\nHow do these new technologies lower the threshold for expertise in carrying out potential attacks?\nWhat are the necessary data points to inform the development of policy frameworks that balance the innovation and risk considerations?\n\nThe second session on November 15 will focus on governance of these emerging technologies\, including challenges in defining regulatory policies as well as approaches to safeguard against these risks. \n\nMeeting Materials\n\n\n\n AI and Biosecurity Webinar_Background Material \nAI and Biosecurity Webinar_Virtual Attendance Best Practices \n\nPlease visit the National Academies’ AI & Biosecurity Webinar Registration (Forum Microbial Threats) website to register for either session.
URL:https://globalbiodefense.com/event/charting-a-responsible-future-in-ai-biosecurity-understanding-technology-capabilities/
CATEGORIES:Webinar-Webcast
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231112
DTEND;VALUE=DATE:20231116
DTSTAMP:20230905T165451Z
CREATED:20230905T165351Z
LAST-MODIFIED:20230905T165451Z
UID:59051-1699747200-1700092799@globalbiodefense.com
SUMMARY:APHA 2023 Annual Meeting & Expo
DESCRIPTION:The 2023 Annual Meeting of the American Public Health Association (APHA 2023) will be held 12-15 November in Atlanta\, Georgia. \nThis year’s premier public health event will be held both in-person and via live and recorded on-demand virtual sessions. \nTopics and sessions highlighted by include: \n\nBuilding partnerships to solve public health emergencies\nAssessing the performance of posterior oral and nasal swabs in a point-of-care tests for SARS-CoV-2\nSupporting equitable public health solutions with saliva-based testing – an innovative\, low-cost\, and scalable testing methodology\nRisk of invasive bacterial infections in under-immunized febrile patients between 2 and 36 months old presenting to the emergency department\nA retrospective geospatial study of chronic wasting disease in Kansas\nQMRA as a tool for probabilistic risk assessment of legionella in drinking and building water distribution systems\nHuman pathogenic bacteria in stream sediments: Teaching beginners the microbiological and bioinformatic methods of public health pathogenomics\nEvaluation for efficacy of field point-of-care malaria diagnostic methods in Ethiopia\nPrevalence and factors associated with HIV testing among sexually experienced high school students in U.S.A.\nLegionella in the Built Environment:  Emerging Research\, Practices\, and Policies\nApplication of systems thinking to investigating and managing legionella risk in cooling towers: Examples from the city and state of New York\nAn integrated vector management program for the prevention and control of the Aedes aegypti mosquito in Puerto Rico\nGut feelings: Investigating diarrhea etiology in low-and middle-income country (LMIC) children\nInsurance coverage and hepatitis b vaccination among Chinese American adults: An analysis of national health interview survey data\nDrug-resistant tuberculosis: A reflection on the development of contemporary treatment policy\nIdentifying the behavioral and social drivers for under-immunized or zero-dose vaccination of children in urban communities of Kathmandu\, Nepal\nDigital health literacy assessment: Insights into the challenges of health informatics in Ukraine\nFactors associated with COVID-19 health misinformation and vaccine hesitancy among hispanic adults in southern California\nPerceived impact of COVID-19 on parental vaccine hesitancy and pediatrician vaccination recommendation behavior\nEffect of positive emotions on vaccine hesitancy: An experimental study with vaccine-hesitant individuals\nUnderstanding geographical information systems (GIS) and its public health informatics applications\nThreats to public health workers\nHarnessing AI for public health preparedness\nLeveraging data to increase supply chain resilience\n\nPlease visit APHA’s Annual Meeting & Expo website to register.
URL:https://globalbiodefense.com/event/apha-2023-annual-meeting-expo/
LOCATION:Georgia World Congress Center\, 285 Andrew Young International Blvd NW\, Atlanta\, GA\, 30313\, United States
CATEGORIES:Conference
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231113
DTEND;VALUE=DATE:20231115
DTSTAMP:20231017T165957Z
CREATED:20231016T173338Z
LAST-MODIFIED:20231017T165957Z
UID:59385-1699833600-1700006399@globalbiodefense.com
SUMMARY:BARDA Industry Day - BID2023
DESCRIPTION:The annual BARDA Industry Day (BID) conference will be held 13-14 November 2023 in Washington DC and via virtual participation. \nBID2023: Driving Innovation for Preparedness & Response will feature presentations from BARDA leadership\, U.S. government partners\, and industry on medical countermeasure (MCM) priorities and public health innovation. Attendees will also have an informal opportunity to interact with BARDA and ASPR teams and identify areas of potential collaboration in the field of MCM research and development. \nThe event lineup will have an assortment of BARDA program briefings\, guest speakers\, networking opportunities\, and specialized breakout sessions. Content will focus on BARDA’s efforts to collaborate across government and industry to continually innovate MCMs to address current and future health security threats. \nBARDA’s Influenza and Emerging Infectious Diseases Division (IEIDD) will give a broad ranging presentation on BARDA’s strategy for vaccine development through licensure including harmonized clinical trials\, centralized immune endpoint assays\, determination of correlates of protection\, lessons learned from the COVID-19 vaccine portfolio\, and assay-generated data for accelerated decision making. \nBARDA’s Division of Chemical\, Biological\, Radiological\, And Nuclear (CBRN) Countermeasures will provide an overview of its strategic priorities for branch and division level efforts. Among these priorities include CBRN’s plans to expand the nation’s capabilities to respond to any CBRN health security incident\, whether naturally occurring or intentional. Following the presentations\, a moderated Q&A panel will provide a deeper dive into how division-level priorities can shape medical countermeasure development going forward. \nBARDA program representatives\, industry partners\, and developers will provide an overview of animal models developed in laboratories of network performers funded through the Biological\, Chemical\, and Radiological Indefinite Delivery/Indefinite Quantity (ID/IQ) contract. In addition\, selected product developers funded by BARDA’s nonclinical network will share information on the use of animal models in efforts to license products for use against biodefense threats. \nBARDA’s Biopharmaceutical Manufacturing Preparedness (BioMaP) program has a three-pronged approach to address key vaccine manufacturing gaps to bring the nation up to the speed and scale required for future public health emergencies. In this session\, the BioMaP team will discuss these three components: the BioMaP-Consortium\, the Exercise (BioMaP-X)\, and the BioMaP Workforce Development (BioMaP-W). Join BARDA’s Pharmaceutical Countermeasures Infrastructure Division (PCI) to learn about these different aspects of the BioMaP program. \nSpeakers from the U.S. Food and Drug Administration’s (FDA) Medical Countermeasures Initiative will also address the coordination of emergency activities involving products regulated by the FDA’s Center for Drug Evaluation and Research (CDER)\, Center for Biologics Evaluation and Research (CBER)\, and Center for Devices and Radiological Health (CDRH). \nThe Division of Chemical\, Biological\, Radiological and Nuclear (CBRN)\, Division of Research\, Innovation and Ventures (DRIVe)\, and Division of Nonclinical Development (DNCD) will discuss microphysiological systems (MPS)/organ chips and how it aligns with BARDA’s portfolio. \nLearn more about BARDA Ventures – Global Health Investment Corporation (GHIC) partnership and join a discussion with GHIC on investment focus\, priorities\, and the landscape of venture investment in global health security. In addition\, learn more about the case study with Cytovale and Endpoint Health demonstrating how BARDA Ventures complements BARDA’s other investment vehicles to support MCM development and commercialization. \nA session on host-based diagnostics in sepsis will illuminate the strategic value of Host-Based Diagnostics (HBDs) in the infectious disease space and how to build a community around demonstrating the clinical utility of HBDs and streamlining their adoption and integration into practice. \nUncover BARDA’s latest initiative in clinical trial innovation pertaining to decentralized trials – the Decentralized Clinical Operations for Healthcare and Research (D-COHRe) strategic partnership. Topics include information on D-COHRe and BARDA’s fundamental interagency work towards advancing pandemic preparedness. \nPlease visit Medicalcountermeasures.gov to register. \n 
URL:https://globalbiodefense.com/event/barda-industry-day-bid2023/
LOCATION:Grand Hyatt Washington\, 1000 H St NW\, Washington DC\, 20001\, United States
CATEGORIES:Government Hosted,Industry Day
ATTACH;FMTTYPE=image/jpeg:https://globalbiodefense.com/wp-content/uploads/2023/10/barda-industry-day-2023.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231114
DTEND;VALUE=DATE:20231119
DTSTAMP:20231028T204037Z
CREATED:20230422T182706Z
LAST-MODIFIED:20231028T204037Z
UID:57061-1699920000-1700351999@globalbiodefense.com
SUMMARY:AMP 2023 Annual Meeting & Expo
DESCRIPTION:The Association for Molecular Pathology (AMP) 2023 Annual Meeting & Expo will be held 14-18 November 2023 in Salt Lake City\, Utah. \nAMP is the leading organization in the field of molecular diagnostics\, and the annual meeting is widely considered the “premier gathering” of molecular professionals. With more than 200 exhibiting companies\, 60 educational sessions\, nearly 400 poster presentations\, and 2\,900+ attendees\, the AMP Annual Meeting & Expo is not to be missed. \nExplore how cutting-edge technology and developments in molecular testing continue to have a major and direct impact on patient care. \nThe event begins November 14 with a Short Course Day\, November 15 is the Corporate Workshop Day. This day features 80+ hours of industry sponsored scientific content. This event is free for Annual Meeting attendees and the local healthcare and scientific communities. November 16-18 contains the Scientific Program. \nPlease visit the AMP 2023 Annual Meeting website for more information and to register.
URL:https://globalbiodefense.com/event/amp-2023-association-molecular-pathology/
LOCATION:Salt Palace Convention Center\, 100 S W Temple St\, Salt Lake City\, UT\, 84101\, United States
CATEGORIES:Conference
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231115T120000
DTEND;TZID=America/New_York:20231115T130000
DTSTAMP:20231030T224910Z
CREATED:20231030T224910Z
LAST-MODIFIED:20231030T224910Z
UID:59422-1700049600-1700053200@globalbiodefense.com
SUMMARY:Negotiating the Pandemic Treaty: Challenges for Consensus and Equity
DESCRIPTION:The Center for Emerging Infectious Diseases (CEID) will host the Negotiating the Pandemic Treaty: Challenges for Consensus and Equity event on 15 November 2023 in Boston\, MA and via webcast. \nThis event features guest lecture by Adam Kamradt-Scott\, PhD. \nProfessor Adam Kamradt-Scott is the Dr Jiang Yanyong Visiting Professor of Global Health Security at the Harvard T.H. Chan School of Public Health. Adam’s research\, teaching\, and policy engagement work explores how governments and multilateral organisations respond to adverse health events such as epidemics\, pandemics\, and emerging health and security challenges. His most recent research has focused on civil-military cooperation in health and humanitarian crises\, and the adoption of international legal instruments for health. \nPrior to entering academia\, Adam’s background includes having worked as a health professional specializing in emergency care and clinical risk management\, a political adviser\, and a public servant in national pandemic preparedness\, and he holds formal academic qualifications in health\, international relations\, and international law. More recently\, he has served as a consultant to the Australian Government and the World Bank on pandemic preparedness and the COVID-19 response\, and he is continuing to advise the Australian Government on the latest proposed changes to the International Health Regulations and the pandemic treaty. \nAdam is the co-founder and convenor of the Global Health Security conferences and currently serves as the Chair of the Board of Directors for the Global Health Security Network\, a multidisciplinary professional association dedicated to promoting evidence-based policies to improve health outcomes. \nRegister to attend the lecture in person or via Zoom.
URL:https://globalbiodefense.com/event/negotiating-the-pandemic-treaty-challenges-for-consensus-and-equity/
LOCATION:Boston University\, 72 East Concord Street R-103\, Boston\, MA\, 02118\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231115T120000
DTEND;TZID=America/New_York:20231115T133000
DTSTAMP:20231102T173613Z
CREATED:20231102T172619Z
LAST-MODIFIED:20231102T173613Z
UID:59439-1700049600-1700055000@globalbiodefense.com
SUMMARY:Charting a Responsible Future in AI & Biosecurity: Enabling Safe Innovation and Governance
DESCRIPTION:The National Academies’ Health and Medicine Division’s Forum on Microbial Threats and the Division of Earth and Life Studies’ Board on Life Sciences will host a webinar on November 15 on Charting a Responsible Future in AI & Biosecurity. \nThis is the second of two sessions bringing together technology developers\, researchers\, and policymakers working at the intersection of foundation model-based artificial intelligence (AI) and biological research to explore the impact of these technologies on innovation\, potential biosecurity risks\, and promising solutions. \nHighlighted agenda items and strategic questions include: \n\nWhat are the risk concerns and challenges from the legal perspective?\nLayered approach to considering policy options\, connecting to benchmarks (e.g.\, functional characterizations of biological applications and tools for their capabilities)\, and building in evaluations to define the characteristics of the tools\nLeveraging foundation models for pandemic preparedness\, rapid development of countermeasures against emerging threats\nWhat still needs to be defined to enable further discussions on regulation?\nWhat are approaches that can be taken to think about regulation and safety?\n\nThe first session on November 6 examined the technological capabilities and bridging the need for risk management between developers and policymakers. \nPlease visit the National Academies’ AI & Biosecurity Webinar Registration (Forum Microbial Threats) website to register. \n\nMeeting Materials\n\n\n\n AI and Biosecurity Webinar_Background Material \nAI and Biosecurity Webinar_Virtual Attendance Best Practices
URL:https://globalbiodefense.com/event/charting-a-responsible-future-in-ai-biosecurity-enabling-safe-innovation-and-governance/
CATEGORIES:Webinar-Webcast
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231128T100000
DTEND;TZID=America/New_York:20231128T110000
DTSTAMP:20231117T215300Z
CREATED:20231117T215300Z
LAST-MODIFIED:20231117T215300Z
UID:59502-1701165600-1701169200@globalbiodefense.com
SUMMARY:Bolivian and Argentinian Hemorrhagic Fevers
DESCRIPTION:Join the National Emerging Special Pathogens Training and Education Center (NETEC) for a webinar on Argentinian hemorrhagic fever (AHF) and Bolivian hemorrhagic fever (BHF) on November 28. \nAHF and BHF are zoonotic diseases with the potential for human-to-human transmission. During this webinar\, guest presenters will describe the epidemiology of AHF and BHF cases\, risk factors\, clinical presentations and management\, and review a public health program model for arenavirus control. Interpretation services will be provided during the event. \nPANELISTS \nAnabel Sinchi\, MD\, MPH\nCristian Castellón Gutierrez\, MD\nMaria (Gaby) Frank\, MD\, FACP\, SFHM – Moderator \nContinuing education credits will be provided for this activity. \nPlease visit NETEC for more information.
URL:https://globalbiodefense.com/event/bolivian-and-argentinian-hemorrhagic-fevers/
CATEGORIES:Webinar-Webcast
LOCATION:https://unmc.zoom.us/webinar/register/WN_HZluRLZcSWK7Kwy-SeI12Q?mc_cid=e4abb4c1d3#/registration/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231205T104500
DTEND;TZID=America/New_York:20231205T150000
DTSTAMP:20231202T164659Z
CREATED:20231202T164659Z
LAST-MODIFIED:20231202T164659Z
UID:59526-1701773100-1701788400@globalbiodefense.com
SUMMARY:Meeting the Moment: Biodefense Policy\, Procurement\, and Public Health
DESCRIPTION:The Bipartisan Commission on Biodefense will host a public meeting on Meeting the Moment: Biodefense Policy\, Procurement\, and Public Health in Washington DC on 5 December 2023. \nThis meeting will focus on addressing vulnerabilities in biodefense in the wake of the COVID-19 pandemic. Topics to be discussed include biodefense policies and activities at the Department of Defense\, federal stockpile evaluation and decision-making for smallpox medical countermeasures\, needed authorities of the Centers for Disease Control and Prevention\, and the need for better national leadership of our biodefense in light of its performance during the COVID-19 pandemic. \n“Ongoing conflicts abroad – including the recent onset of war between Israel and Hamas – and the persistent biological weapons aspirations of enemy nations highlight the need for continued vigilance\, reflection\, and improvement in our ability to address biological threats\,” said former U.S. Senator and Commission Co-Chair Joe Lieberman. “The Department of Defense released the results of their Biodefense Posture Review in August\, with dozens of recommendations for enhancing the protection of warfighters\, situational awareness of the threat\, and support for civilian authorities. The Commission is especially interested in learning at this meeting from Assistant Secretary of Defense Rosenblum more about the Biodefense Council that the Department stood up to facilitate implementation of these recommendations and enhance coordination across the Department.” \nThe meeting will feature remarks by: \n\nThe Honorable Deborah G. Rosenblum\, Assistant Secretary of Defense for Nuclear\, Chemical\, and Biological Defense Programs\, Department of Defense\nThe Honorable W. Craig Vanderwagen\, Managing Director\, East West Protection\, LLC\, and former Assistant Secretary for Preparedness Response\, Department of Health and Human Services\nJulie L. Gerberding\, MD\, MPH\, CEO\, Foundation for the National Institutes of Health\, and former Director\, Centers for Disease Control and Prevention\nJeff Reczek\, Director\, Washington Office\, Centers for Disease Control and Prevention\nLaura Efros\, PhD\, Vice President\, U.S. Government Affairs\, Bavarian Nordic\nPaul Williams\, Senior Vice President\, Products Business\, Emergent BioSolutions\nJay Varma\, MD\, Executive Vice President and Chief Medical Officer\, SIGA Technologies\, Inc.\n\n“Our former colleagues on Capitol Hill continue to debate how best to address the biological threat\,” said former Congressman and meeting Co-Chair Fred Upton. “As Congress considers federal roles and responsibilities\, and as our Commission reassesses our 2015 National Blueprint for Biodefense\, strong leadership and additional authorities are required to solve the problems that arose during the COVID-19 pandemic and better defend the Nation against biological weapons from enemy nations and terrorist organizations.” \nPlease visit the Bipartisan Commission on Biodefense Meeting the Moment: Biodefense Policy\, Procurement\, and Public Health event page to register. This meeting will not be live-streamed.
URL:https://globalbiodefense.com/event/meeting-the-moment-biodefense-policy-procurement-and-public-health/
LOCATION:Convene DC\, 600 14th Street NW\, Suite 600\, Washington DC\, DC\, 20005\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231206T060000
DTEND;TZID=America/New_York:20231206T070000
DTSTAMP:20231202T161805Z
CREATED:20231202T154243Z
LAST-MODIFIED:20231202T161805Z
UID:59522-1701842400-1701846000@globalbiodefense.com
SUMMARY:AMR One Health Priority Research Agenda: Transmission
DESCRIPTION:A webinar on the One Health Priority Research Agenda for AMR will be held 6 December 2023\, part of a series hosted by the Quadripartite organizations. This session will focus on transmission. \nThe Quadripartite organizations\, made up of the Food and Agriculture Organization of the United Nations (FAO)\, United Nations Environment Programme (UNEP)\, World Health Organization (WHO)\, and the World Organisation for Animal Health (WOAH)\, established the Quadripartite Technical Group and developed the One Health Priority Research Agenda for AMR (AMR-OHPRA) a joint initiative to assist in directing and catalyzing scientific interest and financial investments for AMR priority research across sectors for countries and funding bodies. \n\n\nThe research agenda also serves as a guide to prevent and mitigate AMR within the One Health approach that will help policymakers\, researchers\, and a multidisciplinary scientific community to work together on solutions. \nThe webinar will include a panel discussion on the challenges and opportunities that this Agenda brings to the One Health community and how this agenda can attract and motivate donors\, the scientific community\, and governments to support research addressing the specific areas identified on Transmission in the AMR-OHPRA. \nHighlighted agenda items include: \nOpening remarks – George Matheu\, WHO \nAMR-OHPRA Transmission pillar – Francesca Latronico\, FAO \nDiscussion panel: \n\nHeike Schmitt – Delft Technical University\, The Netherlands\nPhil Taylor – Centre for Agriculture and Bioscience International\, UK\nRungtip Chuanchuen – Chulalongkorn University\, Thailand\nAmit Khurana – Centre for Science and Environment\, India\nPilar Donado – Colombian Corporation of Agricultural Research (AGROSAVIA)\, Columbia\n\nRegister for the webinar here.
URL:https://globalbiodefense.com/event/amr-one-health-priority-research-agenda-transmission/
CATEGORIES:Webinar-Webcast
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240108
DTEND;VALUE=DATE:20240111
DTSTAMP:20240106T224238Z
CREATED:20231206T221746Z
LAST-MODIFIED:20240106T224238Z
UID:59580-1704672000-1704931199@globalbiodefense.com
SUMMARY:Biotech Showcase 2024
DESCRIPTION:The Biotech Showcase 2024 investor conference for innovators will be held 8-10 January 2024 in San Francisco and 16-17 January for virtual participants \nThis premier investor conference is a platform for private and micro-mid-cap biotechnology companies\, offering a unique opportunity to showcase innovations and engage one-to-one with investors and biopharmaceutical executives. \nIn attendance at Biotech Showcase\, you’ll find not only executives from biopharmaceutical and life science companies but also private and public company presentations\, investors\, sector analysts\, bankers and industry professionals. \nThrough its specialized showcases—DigiMed Showcase and Seed Showcase—the event also provides convenient access to the life science ecosystem. \nBiotech Showcase is a co-produced by Demy-Colton and EBD Group\, two organizations with a combined experience of over 50 years in producing high-quality programs that foster growth in the biotechnology sector and broader life science industry. \nPlease visit the Biotech Showcase 2024 website for more information.
URL:https://globalbiodefense.com/event/biotech-showcase-2024/
LOCATION:Hilton San Francisco Union Square\, 333 O'Farrell St\, San Francisco\, CA\, 94102\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240115
DTEND;VALUE=DATE:20240120
DTSTAMP:20240111T192843Z
CREATED:20240111T192843Z
LAST-MODIFIED:20240111T192843Z
UID:59610-1705276800-1705708799@globalbiodefense.com
SUMMARY:World Economic Forum Annual Meeting
DESCRIPTION:The 54th Annual Meeting of the World Economic Forum will be held 15-19 January 2024 in Davos-Klosters\, Switzerland. The meeting is accessible to the wider public through the livestreaming of over 200 sessions. \nThis Annual Meeting will welcome over 100 governments\, all major international organizations\, 1000 Forum’s Partners\, as well as civil society leaders\, experts\, youth representatives\, social entrepreneurs\, and news outlets. \nThe meeting convenes under the theme Rebuilding Trust\, accessible to the wider public with over 200 sessions livestreamed – the full programme is available here. \nHighlighted agenda sessions include: \n\nFacing a World Without Antibiotics\nWhen Climate Impacts Your Health\nSupply Chains of the Future\nClimate and Nature: Seed Capital Needed\nProtecting the Vulnerable Online\nSpecial Address by Volodymyr Zelenskyy\, President of Ukraine\nGenerative AI: Steam Engine of the Fourth Industrial Revolution?\n\n\nLast year at Davos\, the word ‘polycrisis‘ was on everybody’s lips as leaders deliberated the cascading and connected crises of the moment. Today\, even as we turn our attention to new crises\, the old ones persist. \n\n\n“At a time when global challenges require urgent solutions\, innovative public-private collaboration is necessary to convert ideas into action. The Forum provides the structure for developing research\, alliances and frameworks that promote mission-driven cooperation throughout the year\,” said Børge Brende\, President\, World Economic Forum. \nMore than 300 public figures will participate this year\, including more than 60 heads of state and government. There will be strong representation from all key regions of the world. \n\nAn estimated 1\,600 business leaders\, including 800-plus of the world’s top CEOs and chairs from the World Economic Forum’s Members and Partners\, will participate. There will also be more than 150 Global Innovators\, Tech Pioneers and Unicorns who are transforming industries. \n\n\nMore than 200 members of the Forum’s Global Shapers\, Young Global Leaders and Social Entrepreneurs communities will join to showcase local innovations and solutions. Also taking part in the meeting will be more than 150 experts and heads of the world’s leading universities\, research institutions and think tanks. More than 40 labour\, nongovernment organization and religious leaders from civil society will take part as well. \n\n\nHeads of civil society organizations include: Kirsten Schuijt\, Director-General\, WWF International; David Miliband\, President\, International Rescue Committee; Luc Triangle\, General Secretary\, International Trade Union Confederation; Tirana Hassan\, Executive Director\, Human Rights Watch. \n\n\nPlease visit the World Economic Forum 2024 Annual Meeting website for more information.
URL:https://globalbiodefense.com/event/world-economic-forum-annual-meeting/
LOCATION:https://www.weforum.org/events/world-economic-forum-annual-meeting-2024/
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240122
DTEND;VALUE=DATE:20240128
DTSTAMP:20240111T173857Z
CREATED:20240111T173650Z
LAST-MODIFIED:20240111T173857Z
UID:59597-1705881600-1706399999@globalbiodefense.com
SUMMARY:WHO Executive Board Meeting
DESCRIPTION:The World Health Organization will convene the 154th session of the WHO Executive Board in Geneva from 22-27 January 2024. \nThe Executive Board is composed of 34 technically qualified members elected for three-year terms. The annual Board meeting is held in January when the members agree upon the agenda for the World Health Assembly (scheduled for May 2024) and the resolutions to be considered by the Health Assembly\, including the 2025-2028 Programme of Work\, sustainable financing\, and global health emergency priorities and processes. \nHighlighted agenda items (links below) include the Draft Global Action Plan for Infection Prevention and Control; Immunization Agenda; Antimicrobial resistance operational priorities 2025-2035; Smallpox eradication: destruction of variola virus stocks; Public health emergencies: preparedness and response; Strengthening the global architecture for health emergency preparedness\, prevention and response and resilience. \nProceedings will be webcast and recorded for on-demand viewing. \n\nThe Executive Board\n\n\n\nChair and Officers of the Executive Board \nComposition of the Executive Board \nEB154/1\nProvisional agenda \nEB154/1 (annotated)\nProvisional agenda (annotated) \nEB154/3\nReport of the regional committees to the Executive Board \nEB154/5\nReport of the Standing Committee on Health Emergency Prevention\, Preparedness and Response \nEB154/6\nUniversal health coverage \nEB154/7\nFollow-up to the political declaration of the third high-level meeting of the General Assembly on the prevention and control of non-communicable diseases\nPrevention and management of noncommunicable diseases\, promotion of mental health and well-being\, and treatment and care of mental health conditions \nEB154/8\nDraft global action plan for infection prevention and control\nDraft global action plan and monitoring framework \nEB154/8 Add.1\nDraft global action plan on infection prevention and control\nDraft global action plan and monitoring framework: minimum requirements for IPC programmes at national and health care facility levels \nEB154/9\nImmunization Agenda 2030\nProgress towards global immunization goals and implementation of the Immunization Agenda 2030 \nEB154/10\nEnd TB Strategy\nProgress in implementing the global strategy and targets for tuberculosis prevention\, care and control after 2015 (the End TB Strategy) \nEB154/11\nRoad map for neglected tropical diseases 2021–2030 \nEB154/12\nAcceleration towards the Sustainable Development Goal targets for maternal health and child mortality \nEB154/13\nAntimicrobial resistance: accelerating national and global responses\nWHO strategic and operational priorities to address drug-resistant bacterial infections in the human health sector\, 2025–2035 \nEB154/14\nWHO’s work in health emergencies\nPublic health emergencies: preparedness and response \nEB154/15\nWHO’s work in health emergencies\nStrengthening the global architecture for health emergency preparedness\, prevention and response and resilience \nEB154/16\nImplementation of resolution WHA75.11 (2022) \nEB154/17\nGlobal Health and Peace Initiative \nEB154/18\nPoliomyelitis\nPoliomyelitis eradication \nEB154/19\nPoliomyelitis\nPolio transition planning and polio post-certification \nEB154/20\nSmallpox eradication: destruction of variola virus stocks \nEB154/21\nSocial determinants of health\nProgress of the World Report on Social Determinants of Health Equity \nEB154/23\nWell-being and health promotion \nEB154/24\nClimate change\, pollution and health\nImpact of chemicals\, waste and pollution on human health \nEB154/25\nClimate change and health \nEB154/27\nFinancing and implementation of the Programme budget 2022–2023 and outlook on financing of the Programme budget 2024–2025 \nEB154/28\nDraft fourteenth general programme of work \nEB154/29 Rev.1\nSustainable financing: WHO investment round \nEB154/32\nMatters emanating from the Agile Member States Task Group on Strengthening WHO’s Budgetary\, Programmatic and Financing Governance\nSecretariat implementation plan on reform \nEB154/33\nMatters emanating from the Agile Member States Task Group on Strengthening WHO’s Budgetary\, Programmatic and Financing Governance\nStrengthening WHO’s budgetary\, programmatic and financing governance: follow-up to the implementation of decision EB152(15) (2023) \nEB154/33 Add.1\nMatters emanating from the Agile Member States Task Group on Strengthening WHO’s Budgetary\, Programmatic and Financing Governance\nProposals for improving the effectiveness of the WHO Governing bodies \nEB154/33 Add.2\nMatters emanating from the Agile Member States Task Group on Strengthening WHO’s Budgetary\, Programmatic and Financing Governance\nProject plan: implementation of digital solutions for interactions between the Secretariat and Member States on matters related to the governing bodies \nEB154/33 Add.3\nMatters emanating from the Agile Member States Task Group on Strengthening WHO’s Budgetary\, Programmatic and Financing Governance\nCost recovery mechanisms for voluntary contributions – an update \nEB154/34\nMatters emanating from the Agile Member States Task Group on Strengthening WHO’s Budgetary\, Programmatic and Financing Governance \nEB154/34 Add.1\nMatters emanating from the Agile Member States Task Group on Strengthening WHO’s Budgetary\, Programmatic and Financing Governance\nFollow-up to decision WHA69(8) (2016)\, operative paragraph (10) \nEB154/34 Add.2\nMatters emanating from the Agile Member States Task Group on Strengthening WHO’s Budgetary\, Programmatic and Financing Governance\nProposed methodology for costing new initiatives/programmes \nEB154/36\nEngagement with non-State actors\nReport on the implementation of the Framework of Engagement with Non-State Actors \nEB154/37\nEngagement with non-State actors\nNon-State actors in official relations with WHO \nEB154/37 Add.1\nFinancial and administrative implications for the Secretariat of decisions proposed for adoption by the Executive Board \nEB154/38\nNomination and appointment of Regional Directors\nProcess for the election of Regional Directors \nEB154/39\nProvisional agenda of the Seventy-seventh World Health Assembly \nEB154/50\nReport on meetings of expert committees and study groups\nReport by the Director-General \nEB154/50 Add.1\nReport on meetings of expert committees and study groups\nExpert advisory panels and committees and their membership
URL:https://globalbiodefense.com/event/who-executive-board-meeting/
LOCATION:https://www.who.int/about/accountability/governance/executive-board/executive-board-154th-session
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240123
DTEND;VALUE=DATE:20240124
DTSTAMP:20240623T231054Z
CREATED:20240111T194643Z
LAST-MODIFIED:20240623T231054Z
UID:59614-1705968000-1706054399@globalbiodefense.com
SUMMARY:OECD High-Level Policy Forum: Better Policies for More Resilient Health Systems
DESCRIPTION:The Organisation for Economic Co-operation and Development (OECD) will host a Ministerial Meeting on Better Policies for More Resilient Health Systems on 23 January 2024 in Paris\, France and via virtual broadcast. \nAs the world emerges from the biggest public health emergency in more than a century\, it is clear that there are lessons to be learned. The COVID-19 crisis exposed significant weaknesses in health systems\, calling for urgent action to ensure that they more resilient to future shocks. At the same time\, global megatrends such as climate change\, demographic change and increased digitalisation will likely have significant implications for health and healthcare in the years to come. \nIn January 2024\, Health Ministers from OECD and partner countries will come together to discuss the legacy and lessons learned from the COVID-19 crisis\, the health policy challenges that lie ahead\, and the actions needed to address them. The meeting will be Chaired by Belgium\, with Australia\, Chile\, Germany\, Norway and Slovenia serving as Vice-Chairs. \nHighlighted agenda items include: \n\nBolstering public health: Healthy populations for more resilient health systems\nThe future of digital health after COVID-19\nThe future of pharmaceutical policy\n\n“Our health systems have continuously improved over recent decades\, both in terms of investment and outcomes. Many have worked tirelessly to make that happen. Nevertheless\, the COVID-19 pandemic was a sobering reminder: fundamental challenges on issues such as workforce\, prevention and health promotion\, mental health\, inequalities and the supply chain of medical goods continue to put pressure on our health systems\,” notes Frank Vandenbroucke\, Chair of the 2024 OECD Health Ministerial Meeting. “If we want to make our health systems more future-proof\, we must take these challenges seriously – especially in the context of rapid social\, technological and environmental change.” \nThe OECD High-Level Policy Forum on The Future of People-Centred Health Innovation will take place on 22 January 2024\, on the eve of the OECD Health Ministerial Meeting. The Forum will explore policies and priorities for adopting new innovations into health systems and is being organised by the OECD\, in collaboration with the Commonwealth Fund and the Health Foundation and in partnership with Financial Times Live. \nPlease visit the OECD Ministerial Meeting page for more information and to register.
URL:https://globalbiodefense.com/event/oecd-high-level-policy-forum-better-policies-for-more-resilient-health-systems/
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240130T133000
DTEND;TZID=America/New_York:20240130T144500
DTSTAMP:20240623T230714Z
CREATED:20240126T225333Z
LAST-MODIFIED:20240623T230714Z
UID:59713-1706621400-1706625900@globalbiodefense.com
SUMMARY:Kazakhstan’s Actions to Address Nuclear and Biological Risks
DESCRIPTION:The Carnegie Endowment and the Council on Strategic Risks will host a panel on Kazakhstan’s increasingly global role in the changing threat landscape of weapons of mass destruction on 30 January 2024 in Washington DC and by webcast. \nUpon the 1991 collapse of the Soviet Union\, Kazakhstan found itself in possession of the world’s fourth-largest nuclear weapons stockpile and the former union’s most significant biological weapons factory. Kazakhstan’s subsequent decision to return and dismantle these weapons has solidified its position as a leader in nuclear and biological risk reduction. For the last thirty years\, Kazakhstan’s actions have served as a core model for regional and international security. \nThe discussion will feature Kazakhstan’s Ambassador to the United States of America Yerzhan Ashikbayev\, the Honorable Andrew Weber\, and Dr. Toghzan Kassenova. It will be moderated by Shannon Green\, senior fellow at the Council on Strategic Risks. \nPlease visit the Carnegie Endowment’s Kazakhstan’s Actions to Address Nuclear and Biological Risks event page to RSVP.
URL:https://globalbiodefense.com/event/kazakhstans-actions-to-address-nuclear-and-biological-risks/
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20240201T120000
DTEND;TZID=Europe/Paris:20240201T130000
DTSTAMP:20240125T192454Z
CREATED:20240125T192454Z
LAST-MODIFIED:20240125T192454Z
UID:59695-1706788800-1706792400@globalbiodefense.com
SUMMARY:WHO Update on COVID-19
DESCRIPTION:A World Health Organization (WHO) update on COVID-19 will be held 1 February 2024 via an EPI-WIN webinar. \nCOVID-19 remains a major public health concern. WHO experts will address what variants are circulating\, their risk and impact\, and what can be done to prevent and protect against infections\, severe disease\, post-COVID-19 condition and deaths. The experts will also address common concerns from the public. \nSpeakers: \n\nDr Maria Van Kerkhove\, Director (a.i.)\, Department of Epidemic and Pandemic Preparedness and Prevention (EPP)\, WHO\nDr Janet Diaz\, Unit Head\, Clinical Management\, WHO\nDr Lorenzo Subissi\, Technical Officer\, EPP\, WHE\, WHO (TBC)\nMs Vicky Houssiere\, Technical Officer\, Risk Communication and Community Engagement (RCCE)\, WHE\, WHO\nMs Shagun Khare\, Communications Officer\, WHE\, WHO\n\nPlease visit the EPI-WIN webinar: WHO update on COVID-19 event page to register. This webinar will be livestreamed on the WHO YouTube channel.
URL:https://globalbiodefense.com/event/who-update-on-covid-19/
LOCATION:https://who.zoom.us/webinar/register/WN_ULS7nOrqRCaw2H9lUZmO7w#/registration
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240202
DTEND;VALUE=DATE:20240203
DTSTAMP:20240201T190248Z
CREATED:20240201T190201Z
LAST-MODIFIED:20240201T190248Z
UID:59787-1706832000-1706918399@globalbiodefense.com
SUMMARY:Meeting of the Committee on the Current State of Research\, Development\, and Stockpiling of Smallpox Medical Countermeasures
DESCRIPTION:This is a closed session\, virtual meeting of the Committee on the Current State of Research\, Development\, and Stockpiling of Smallpox Medical Countermeasures. \nThe meeting is an activity of an ad hoc committee of the National Academies of Sciences\, Engineering\, and Medicine charged with conducting a study to examine lessons learned from the recent COVID-19 pandemic and mpox multi-country outbreak to inform an evaluation of the current state of research\, development\, and stockpiling of smallpox medical countermeasures (MCMs). \nThe committee will consider how the COVID-19 pandemic and the mpox multi-country outbreak can inform improvements to smallpox readiness and response\, including the availability of smallpox MCMs and the ability to meet potential demand. \nThe committee will further examine the current state of MCMs for the diagnosis\, prevention\, and treatment of smallpox\, including: \n\nHow the mpox outbreak altered assumptions about the efficacy and utility of smallpox MCMs\nThe continued role of live Variola virus for research and public health purposes\nImplications for the composition of smallpox MCMs in the U.S. Strategic National Stockpile (SNS)\n\nThe benefits and risks of scientific and technological advances on smallpox readiness and response will be addressed and the committee will identify key priorities in research and development of smallpox MCMs. \nBuilding on the Institute of Medicine’s previous reports\, Assessment of Future Scientific Needs for Live Variola Virus (1999) and Live Variola Virus: Considerations for Continuing Research (2009)\, and a review of existing literature\, analyses\, and other expert and public input\, the committee will develop a report with its findings and conclusions on priorities for additional research or activities to improve the U.S. Government readiness and response posture against smallpox\, and on the composition of the SNS to ensure appropriate smallpox MCM response options. \nPlease visit the National Academies’ Meeting 5 of the Committee on the Current State of Research\, Development\, and Stockpiling of Smallpox Medical Countermeasures event page for more information.
URL:https://globalbiodefense.com/event/meeting-of-the-committee-on-the-current-state-of-research-development-and-stockpiling-of-smallpox-medical-countermeasures/
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Denver:20240205T170000
DTEND;TZID=America/Denver:20240205T183000
DTSTAMP:20240202T221754Z
CREATED:20240202T221754Z
LAST-MODIFIED:20240202T221754Z
UID:59867-1707152400-1707157800@globalbiodefense.com
SUMMARY:Investigating Public Health Mysteries in a Globalized World
DESCRIPTION:The Scowcroft Institute of International Affairs at the Bush School of Government & Public Service at Texas A&M University will host Katherine Eban as she discusses “Investigating Public Health Mysteries in a Globalized World” on February 5\, 2024\, at 5:30 p.m. at the Annenberg Presidential Conference Center. \nAmericans want high-quality\, affordable medication and safety from infectious diseases. But those public health goals are increasingly impacted by far-distant events\, and far different regulatory cultures from our own. Katherine Eban\, an award-winning investigative journalist\, will describe the challenges and rewards of investigating big public health stories that have international and national security repercussions. \nAbout the speaker: \nKatherine Eban \nKatherine Eban\, an investigative journalist\, is a Vanity Fair special correspondent and Andrew Carnegie fellow. Her reporting on generic drug fraud\, gun trafficking\, coercive CIA interrogations\, and COVID-19’s origins has won international attention and numerous awards\, including from the National Association of Science Writers\, the Overseas Press Club\, Investigative Reporters & Editors and Newswomen’s Club of New York. Her 2019 book\, Bottle of Lies: The Inside Story of the Generic Drug Boom\, was a New York Times bestseller. A Rhodes Scholar educated at Brown University and Oxford University\, she lives in New York with her husband\, two daughters and Newfoundland dog\, Romeo. \nPlease visit the Texas A&M Bush School of Government & Public Service’s Investigating Public Health Mysteries in a Globalized World event page to RSVP.
URL:https://globalbiodefense.com/event/investigating-public-health-mysteries-in-a-globalized-world/
LOCATION:Annenberg Presidential Conference Center\, 1002 Bush Drive West\, College Station\, TX\, 77845\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240206
DTEND;VALUE=DATE:20240208
DTSTAMP:20240201T205734Z
CREATED:20240201T202039Z
LAST-MODIFIED:20240201T205734Z
UID:59796-1707177600-1707350399@globalbiodefense.com
SUMMARY:Processes to Evaluate the Safety and Efficacy of Drugs for Rare Diseases or Conditions - Third Meeting
DESCRIPTION:This is the third meeting of the committee of experts and will be conducted virtually. The meeting will include a closed and public session. There will be an opportunity for interested stakeholders to share public comments with the committee on February 7\, 2024 at 12:00 p.m. \nPublic comments will provide the committee with additional insight into key issues related to the study’s statement of task. These include\, but are not limited to: \n\nThe use of regulatory flexibilities and supplementary data (e.g.\, natural history studies and patient registries) when evaluating the safety and efficacy of drugs for rare diseases and conditions\nFDA and EMA engagement of people with lived experience when developing guidance\, policies\, and programs.\n\nPublic comments\, alongside other materials stakeholders have shared\, will be reviewed by the committee\, and may help inform committee deliberations on the statement of task. All comments and materials shared with the committee will be made publicly available in accordance with institutional policies. \nPlease visit NASEM’s Processes to Evaluate the Safety and Efficacy of Drugs for Rare Diseases or Conditions in the United States and the European Union event page for more information on public comments for this meeting. \nOPEN SESSION AGENDA HIGHLIGHTS \n\nLongitudinal trial design\nMaster protocols for drug development trials\nExternal controls for drug development trials\nConsiderations for pediatric trials: caregiver perspective\nConsiderations for pediatric trials: regulatory science perspective\nConsiderations for pediatric trials: industry perspective\nExpanded access programs\nPatient registries and natural history data\nPatient experience data\nModel-informed drug development\nAnalysis methods – causal inference\nFlexibilities applied at FD\n\nABOUT THE COMMITTEE \nIn response to a Congressional request\, an ad hoc committee of the National Academies of Sciences\, Engineering\, and Medicine is conducting a study on processes for evaluating the safety and efficacy of drugs for rare diseases or conditions in the United States and the European Union. \nThe committee will evaluate: \n\nFlexibilities\, authorities\, or mechanisms available to regulators in the United States and the European Union applicable to rare diseases or conditions;\nThe consideration and use of supplemental data submitted during review processes in the United States and the European Union\, including data associated with open label extension studies and expanded access programs specific to rare diseases or conditions.\nAn assessment of collaborative efforts between United States and European Union regulators related to: product development programs under review; policies under development and those recently issued; and scientific information related to product development or regulation.\n\nBased on its information gathering and internal deliberations\, the committee will develop a report with its findings\, conclusions\, and recommendations for actions that Congress\, federal agencies\, the pharmaceutical industry\, and nongovernmental organizations can take to support collaborative efforts. \nPlease visit the National Academies’ Processes to Evaluate the Safety and Efficacy of Drugs for Rare Diseases or Conditions in the United States and the European Union event page for more information. \nThe Fourth Meeting of the committee will be held 3-4 April 2024. \nThe Fifth Meeting of the committee will be held 23-24 May 2024.
URL:https://globalbiodefense.com/event/processes-to-evaluate-the-safety-and-efficacy-of-drugs-for-rare-diseases-or-conditions-in-the-united-states-and-the-european-union/
LOCATION:
END:VEVENT
END:VCALENDAR